Successful multi-target therapy using corticosteroid, tacrolimus, cyclophosphamide, and rituximab for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis.

MLA

Ryu Watanabe, et al. “Successful Multi-Target Therapy Using Corticosteroid, Tacrolimus, Cyclophosphamide, and Rituximab for Rapidly Progressive Interstitial Lung Disease in a Patient with Clinically Amyopathic Dermatomyositis.” Modern Rheumatology, vol. 26, no. 3, May 2016, pp. 465–66. EBSCOhost, https://doi.org/10.3109/14397595.2015.1012797.

APA

Ryu Watanabe, Tomonori Ishii, Kyoko Araki, Mariko Ishizuka, Yukiko Kamogawa, Yoko Fujita, Hiroshi Fujii, & Hideo Harigae. (2016). Successful multi-target therapy using corticosteroid, tacrolimus, cyclophosphamide, and rituximab for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. Modern Rheumatology, 26(3), 465–466. https://doi.org/10.3109/14397595.2015.1012797

Chicago

Ryu Watanabe, Tomonori Ishii, Kyoko Araki, Mariko Ishizuka, Yukiko Kamogawa, Yoko Fujita, Hiroshi Fujii, and Hideo Harigae. 2016. “Successful Multi-Target Therapy Using Corticosteroid, Tacrolimus, Cyclophosphamide, and Rituximab for Rapidly Progressive Interstitial Lung Disease in a Patient with Clinically Amyopathic Dermatomyositis.” Modern Rheumatology 26 (3): 465–66. doi:10.3109/14397595.2015.1012797.